Park, Wungki http://orcid.org/0000-0002-8006-3102
Mezquita, Laura
Okabe, Naoyuki
Chae, Young Kwang
Kwon, Deukwoo
Saravia, Diana
Auclin, Edouard
Planchard, David
Caramella, Caroline
Ferrara, Roberto
Agte, Sarita
Oh, Michael
Mudad, Raja
Jahanzeb, Mohammad
Suzuki, Hiroyuki
Besse, Benjamin
Lopes, Gilberto
Article History
Received: 21 January 2019
Revised: 23 September 2019
Accepted: 29 October 2019
First Online: 25 November 2019
Competing interests
: L.M. served for advisory board/educational sessions for Bristol-Myers Squibb, AstraZeneca and Roche diagnostics, during the conduct of the study and outside the submitted work. Y.C. received research funding from Abbvie, Bristol-Myers Squibb, Biodesix, Lexent Bio, Freenome, Honoraria/Advisory Boards from Roche/Genentech, AstraZeneca, Foundation Medicine, Counsyl, Neogenomics, Guardant Health, Boehringher Ingelheim, Biodesix, immuneoncia, Hanmi, Merck and Takeda during the conduct of the study and outside the submitted work. D.P. served for advisory board/educational sessions for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, priME Oncology, Peer CME and Roche, received honoraria for AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME and Roche and Clinical trials research fund from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, Novocure and Daiichi Sankyo, and received support for Travel/Accommodations from AstraZeneca, Roche, Novartis, prIME Oncology and Pfizer during the conduct of the study and outside the submitted work. R.M. served for advisory board for AstraZeneca, Boehringher Ingelheim, Guardant health and Novartis outside the submitted work. M.J. received research funding from Lilly, Abbvie, Genentech, grants and other from Abbvie, Novartis, Genentech, and Ipsen during the conduct of the study and outside the submitted work. B.B. received research funding from Abbvie, AMGEN, AstraZeneca, BIOGEN, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharma during the conduct of the study and outside the submitted work. G.L. received research funding from Merck during the conduct of the study and outside the submitted work. The authors whose names are listed immediately below certify that they have no affiliations with or involvement in any organisation or entity with any financial interest. W.P., N.O., D.K., D.S., E.A., C.C., R.F., S.A., M.O. and H.S.
: Local Institutional Review Board approved for this study at each participating institution in accordance with the tenets of the Declaration of Helsinki. The local institutional review board number at the University of Miami was 20170427. ‘Commission Scientifique des Essais Thérapeutiques' (CSET), the Institutional Review Board of Institut Gustave Roussy and the IRB confirmed that there were no elements in this retrospective study in conflict with medical ethics. Informed consent was not necessary, due to the retrospective nature of the items analysed that are part of the patients’ routine care. At Fukushima Medical University, the IRB number was 29384 and at Northwestern University, it was STU00207117.
: Funding support by Sylvester Comprehensive Cancer Center Fund.
: Not applicable.
: All the data supporting our findings are included within the paper. The datasets used and/or analysed during this study are available from the corresponding author on reasonable request.